Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicenter trial.
Fiche publication
Date publication
février 2021
Journal
Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier, Pr LEPAGE Côme, Dr ROMAIN Benoit
Tous les auteurs :
Karoui M, Gallois C, Piessen G, Legoux JL, Barbier E, De Chaisemartin C, Lecaille C, Bouche O, Ammarguellat H, Brunetti F, Prudhomme M, Regimbeau JM, Glehen O, Lievre A, Portier G, Hartwig J, Goujon G, Romain B, Lepage C, Taieb J,
Lien Pubmed
Résumé
Neoadjuvant chemotherapy has proven valuable in locally advanced resectable colon cancer (CC) but its effect on oncological outcomes is uncertain. We report the 3-year oncological outcomes of the PRODIGE 22 trial.
Mots clés
Colon cancer, colectomy, neoadjuvant chemotherapy, survival
Référence
Colorectal Dis. 2021 Feb 13;: